People who still developed COVID-19 while taking Xocova after a household exposure had lower peak virus levels and were less likely to report severe symptoms than those taking a placebo, according to new exploratory analyses released by drugmaker Shionogi on October 21. The company, which sponsored the original trial, presented the findings at IDWeek 2026 in Washington, D.C.
The new data address a question many families have as respiratory virus season ramps up. If a household member takes the five-day pill after an exposure and still gets infected, how sick are they likely to get, and does the drug still help? These early numbers point to milder illness in those breakthrough cases, but the analyses were small, were not main goals of the trial and were not designed to prove a benefit.
